Can we talk about the tape on his stick because like yessss love to see it youtube.com/shorts/MscLF...
back on my ice 🏒 #CORTIS #코르티스
YouTube video by CORTIS
youtube.com
March 22, 2026 at 4:57 PM
Can we talk about the tape on his stick because like yessss love to see it youtube.com/shorts/MscLF...
Breaking News: ( OTC: #MSCLF ) Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247
#StockMarket #News
#StockMarket #News
December 11, 2024 at 3:40 PM
In a recent @CheckRare feature, Satellos CMO Dr. Wildon Farwell discusses the science behind SAT-3247 and how restoring the #muscleregeneration process could offer a new therapeutic approach for people living with #Duchenne #FSHD $msclf $mscl Watch the interview checkrare.com/new-treatmen...
New Treatment Option (SAT-3247) for Duchenne Muscular Dystrophy Shows Promise in Early Phase Trial
Wildon Farwell, MD, CMO at Satellos, discusses the safety and efficacy of SAT-3247, a new treatment option for Duchenne muscular dystrophy.
checkrare.com
January 23, 2026 at 1:37 AM
In a recent @CheckRare feature, Satellos CMO Dr. Wildon Farwell discusses the science behind SAT-3247 and how restoring the #muscleregeneration process could offer a new therapeutic approach for people living with #Duchenne #FSHD $msclf $mscl Watch the interview checkrare.com/new-treatmen...
Satellos Announces First Participant with Duchenne Muscular Dystrophy (DMD)Dosed in the Phase 1b Clinical Trial of SAT-3247
Up to 10 adult participants with genetically confirmed DMD to be enrolled in the now ongoing Phase 1b trial in DMD patients www.businesswire.com/news/home/20... #DMD #Muscle
Up to 10 adult participants with genetically confirmed DMD to be enrolled in the now ongoing Phase 1b trial in DMD patients www.businesswire.com/news/home/20... #DMD #Muscle
Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic a
www.businesswire.com
December 11, 2024 at 12:33 PM
Satellos Announces First Participant with Duchenne Muscular Dystrophy (DMD)Dosed in the Phase 1b Clinical Trial of SAT-3247
Up to 10 adult participants with genetically confirmed DMD to be enrolled in the now ongoing Phase 1b trial in DMD patients www.businesswire.com/news/home/20... #DMD #Muscle
Up to 10 adult participants with genetically confirmed DMD to be enrolled in the now ongoing Phase 1b trial in DMD patients www.businesswire.com/news/home/20... #DMD #Muscle
Feb 3 screen showed bullish expansion across trend and SMA crossovers. In 50-200 SMA $SJ +21.8% vol +114%, $CBUS +19.6%, $ISPR +19.1%. $HOMB and $SUI volumes doubled. $BTF +343% in two weeks; $CRVS, $MOVE, $BOIL 3-digit gains. $USAX, $MSCLF +65% with outsized volume, multiday strength.
February 3, 2026 at 3:05 PM
Feb 3 screen showed bullish expansion across trend and SMA crossovers. In 50-200 SMA $SJ +21.8% vol +114%, $CBUS +19.6%, $ISPR +19.1%. $HOMB and $SUI volumes doubled. $BTF +343% in two weeks; $CRVS, $MOVE, $BOIL 3-digit gains. $USAX, $MSCLF +65% with outsized volume, multiday strength.